{
    "nct_id": "NCT03079999",
    "official_title": "Prospective, Randomized, Placebo-Controlled Phase II Trial of Aspirin for Vestibular Schwannomas",
    "inclusion_criteria": "* Radiographic diagnosis of vestibular schwannoma (NF2-associated or sporadic).\n* Ageâ‰¥12 years.\n* Ability to provide informed consent.Pediatric patients must provide assent in addition to their parents'/guardians' consent. Adult patients who cannot consent for themselves will not be eligible to participate in this study.\n* Ability to swallow tablets.\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Inability to perform volumetric measurements of vestibular schwannoma(s).\n* Inability to tolerate MRI with contrast.\n* Daily use of aspirin within the last two months. Occasional use of aspirin for pain relief is not exclusionary.\n* Known allergy to aspirin.\n* Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of aspirin.\n* Pregnant or lactating women.\n* Patients with serious medical illnesses (e.g. severe asthma) that in the option of the investigator could prevent participation in the trial.\n* Active bleeding diathesis.\n* Hydrocephalus from brainstem compression.\n* Febrile illness or flu-like illness in children and adolescents less than 18 years of age.",
    "miscellaneous_criteria": ""
}